Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
33.52
-0.35 (-1.03%)
Mar 9, 2026, 3:07 PM EDT - Market open
Corcept Therapeutics Revenue
In the year 2025, Corcept Therapeutics had annual revenue of $761.41M with 12.79% growth. Corcept Therapeutics had revenue of $202.13M in the quarter ending December 31, 2025, with 11.12% growth.
Revenue (ttm)
$761.41M
Revenue Growth
+12.79%
P/S Ratio
4.69
Revenue / Employee
$1,043,023
Employees
730
Market Cap
3.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 761.41M | 86.37M | 12.79% |
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 909.05M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Centessa Pharmaceuticals | 15.00M |
| Crinetics Pharmaceuticals | 7.70M |
| Xenon Pharmaceuticals | 7.50M |
CORT News
- 6 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT - PRNewsWire
- 12 days ago - Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update - Business Wire
- 17 days ago - Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not - Seeking Alpha
- 17 days ago - Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals - Business Wire
- 18 days ago - Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Benzinga
- 19 days ago - Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 4 weeks ago - CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewsWire